|
市場調查報告書
基因療法：世界最新發展狀況與市場潛力
Gene Therapy: Worldwide Current Development Status and Market Potential
|
本報告已在2011年07月19日停止出版。
基因療法在這十年內普獲得市場承認，確實往當初導入方向前進。
專門提供有供最新的醫藥品與醫療技術情報分析和解決方法的MedMarket Diligence（總公司：美國加州），分析遺傳基因療法的發展狀況與有關商業應用評價，並發行了調查報告書"Gene Therapy: Worldwide Current Development Status and Market Potential"。
該報告書將遺傳基因療法的方法、技術、臨床目標、競爭企業、臨床的/商業的障礙、未來10年的預測等做了調查分析，全書含40個圖表共265頁，概略內容如下所載：
1. 遺傳基因療法的概論
2. 科技
3. 遺傳基因配送：病毒
- Adenovirus
- 伴隨著adenovirus的病毒
- Retrovirus
- 單純疱疹細胞
- Wrench virus
- RNA細胞
- 主要開發企業
4. 遺傳基因配送：非病毒
- 細胞
- Ribosome
- DNA
- 其他 Vector
- 主要開発企業
5. 臨床目標：單一遺傳基子缺乏症
6. 臨床標的：癌
- 乳癌
- 前立腺癌
- 黑色腫瘤
- 肺癌
- 頭頸部癌
- 其他癌症
7. 臨床目標：感染症
8. 其他的臨床標的
9. 市場機會
- 目標疾病的罹患率
- 市場潛在力
- 產品開發的主導企業
- 遺傳基因治療界的企業
10. 課題
11. 企業策略
12. 未來預測
While research and development of gene therapy has experienced its share of hurdles in recent years, it has also begun demonstrating its potential.
As a result of the technical sophistication and aggressive development by commercial and academic entities, the continued financial support evincing
its real promise, and the unabated clinical need of numerous patient populations, gene therapy is indeed headed toward market approval and
introduction by the end of this decade.
This report will be a detailed assessment of the status of development in gene therapy and the outlook for its commercial introduction. The
report will detail the techniques, technologies, and target clinical applications being pursued, with detailed data and insights on specific products
and the numerous competitors vying to reach the market. The report will provide a well-grounded assessment of the remaining clinical and
commercial hurdles, providing a ten-year outlook for genetically based therapies. The report's analysis will reveal windows of opportunity for current
or hopeful competitors. Executive Summary
Section 1: Introduction to Gene Therapy
- History
- Technologies
- Clinical targets
- Challenges
- The ethical and regulatory dimension
Section 2: Technology
- Gene insertion
- Genes to correct deficiencies
- Genes to enhance immune function
- Gene targeting
- Gene silencing
- Antisense compounds
- RNA interference
Section 3: Gene Delivery: Viral Vectors
- Adenoviruses
- Adeno-associated viruses
- Retroviruses
- Herpes simplex virus
- Lentiviruses
- RNA viruses
- Main companies developing viral vectors
- AlphaVax Inc
- ALZA Corporation
- AMDL Inc
- Amsterdam Molecular Therapeutics
- Applied Genetic Technologies Corporation
- Ariad Gene Therapeutics
- Ark Therapeutic
- Austrianova Biotherapeutics
- AVAX Technologies
- Aventis Gencell
- Avigen Inc
- Bavarian Nordic A/S
- BD Biosciences Clontech
- Biogen-IDEC
- Canji Inc
- Cell Genesys Inc
- Ceregene Inc
- Collateral Therapeutics Inc
- Crucell NV
- DNAVEC Research Inc
- Enzo Biochem Inc
- GenEra S.p.A.
- Genetic Therapy Inc
- Genetix Pharmaceuticals Inc
- GenVec Inc
- Genzyme Corp.
- Got-a-Gene AB
- Henogen
- Imgenex In.
- Introgen Therapeutics Inc
- InvivoGen
- MediGene AG
- Merck & Co Inc
- MFIC Corporation
- ML Laboratories
- Molecular Medicine Bioservices Inc
- Nature Technology Corporation
- Onyx Pharmaceuticals
- Oxford Biomedica plc
- Phogen Ltd
- Qbiogene
- Takara Biomedical Group
- Targeted Genetics Corporation
- Therion Biologics Corporation
- Transgene S.A.
- VIRxSYS Corporation
Section 4: Gene Delivery: Non-Viral Vectors
- Cells
- Liposomes
- DNA
- Other vectors
- Main companies developing non-viral vectors
- Cells
- Ariad Gene Therapeutics
- Cardion AG
- CellGenix Technologie Transfer GmbH
- Enzo Biochem Inc
- GenEra S.p.A.
- ML Laboratories
- NeuralSTEM Inc
- Neurotech SA
- NsGene A/S
- Schering AG
- Sirna Therapeutics (formerly Ribozyme Pharmaceutical Inc
- Targeted Genetics Corporation
- Liposomes
- AntiCancer Inc
- G.O.T. GmbH & Co. KG
- Genteric Inc
- Genzyme Corp.
- IC-Vec Ltd
- Imperial College Innovations Ltd
- Invitrogen Inc
- ML Laboratories
- Polyplus-transfection SAS
- Qbiogene
- Qiagen
- Regulon Inc
- Targeted Genetics Corporation
- Transgene
- Valentis Inc
- Vical Incorporated
- DNA
- Aldevron LLC
- Althea Technologies Inc
- Copernicus Therapeutics Inc
- CytRx Corporation
- Genencor International Inc
- Mirus Corporation
- Mologen Holding AG
- Nucleonics Inc
- Qiagen
- Supratek Pharma Inc
- Tosk Inc
- Transkaryotic Therapies (TKT) Inc
- Vical Incorporated
- Wyeth Lederle Vaccines
- Other Vectors
- Athersys Inc
- Chromos Molecular Systems Inc
- Expression Genetics Inc
- Insert Therapeutics Inc
- Intradigm Corporation
- REPLICor Inc
- Sangamo BioSciences Inc
- Symbiontics Inc
- Vion Pharmaceuticals Inc
Section 5: Clinical Targets: Single-Gene Deficiencies
- Cystic fibrosis
- Other diseases
section 6: Clinical Targets: Cancers
- Breast cancer
- Prostate cancer
- Melanoma
- Lung cancer
- Head & Neck cancer
- Other cancers
Section 7: Clinical Targets: Infections
- HIV/AIDS
- Other infections
Section 8: Other Clinical targets
- Cardiovascular conditions
- CNS conditions
- Tissue repair
- Other
Section 9: Market Opportunities
- Prevalence of major target diseases
- Market potential for gene therapies
- Leading companies in product development
- Companies serving the gene therapy industry
Section 10: Challenges
- Technical hurdles
- Adverse events
- The ethical debate
- Regulatory and patent issues
Section 11: Company Profiles (Partial List)
- US Companies
- Aastrom
- AlphaVax
- Alza
- Ariad
- Aventis Gencell
- Avigen
- Bio-Rad
- Cell Genesys, Inc.
- Collateral Therapeutics
- Copernicus Therapeutics
- Corautus Genetics
- CytoGenix
- Enzo Biochem
- Gene Therapy Systems
- Genetronics Biomedical Corp.
- GenVec, Inc.
- Genzyme Corp.
- Introgen Therapeutics
- InVivogen
- Merck & Co
- Mirus
- Onyx Pharmaceuticals
- RheoGene
- Schering Plough
- Selective Genetics
- Sirna Therapeutics
- Targeted Genetics
- Valentis
- Vical
- European companies
- AustriaNova Biotherapeutics
- Bavarian Nordic
- NSGene
- Transgene
- MolMed
- Modex Therapeutics
- ML Laboratories
- Oxford Biomedica
- Phogen
- Canadian companies
- AngioGene
- Chromos Molecular Systems
- Australian companies
- Antisense Therapeutics
- Benitec
- Asian company
Section 12: The Future
- Expert Views
- Technologies Most Likely to Succeed
- Clinical Targets Most Likely to Benefit
- Companies Most Likely to Prosper
Appendix I: Science Background to Gene Therapy
Appendix II: Glossary
Appendix III: Company Addresses
|
